AstraZeneca’s Fasenra Achieves Primary Objective in Phase III Trial in EGPA
The MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreCoya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read moreReCode Therapeutics, announced the dosing of the first participants in a Phase 1 trial designed to evaluate the safety and
Read moreMachine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
Read morePfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
Read moreFrench clinical-stage biotech company Sensorion, which focuses on the creation of cutting-edge treatments to manage, prevent, and reverse hearing loss
Read morePfizer Inc. (NYSE: PFE) announced in late December, positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene
Read moreApogenix, a biopharmaceutical company developing next-gen immunotherapeutics, announced on Wednesday that asunercept showed statistically meaningful benefits for hospitalized COVID-19 patients
Read moreThe first doses of an experimental HIV vaccine antigen have been provided in a clinical study at George Washington University
Read moreA next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
Read more